Description
Umifenovir Pharmacodynamics
Antiviral agent.
Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1) pdm09 and A(H5N1), and other viruses – causative agents of acute respiratory viral infections (ARI) (coronavirus (Coronavirus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus).
By the mechanism of antiviral action refers to fusion inhibitors (fusion), it interacts with hemagglutinin of the virus and prevents fusion of the lipid shell of the virus and cell membranes.
It has a moderate immunomodulatory effect, increases the body’s resistance to viral infections. It has interferon-inducing activity: in a study on mice, interferon induction was observed after 16 hours, and high interferon titers were maintained in blood up to 48 hours after injection. It stimulates cellular and humoral immune reactions: it increases the number of lymphocytes in blood, especially the number of T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK-cells).
Therapeutic efficacy in viral infections is manifested in reduction of duration and severity of the course of the disease and its main symptoms, as well as in reduction of the frequency of complications associated with viral infection and exacerbations of chronic bacterial diseases.
During treatment of influenza or acute respiratory viral infections in adult patients a clinical study showed that the effect of umifenovir in adult patients is most pronounced in the acute period of the disease and is manifested by a reduction in the time of resolution of disease symptoms, reduced severity of manifestations of the disease and a reduction in the time of elimination of the virus.
Therapy with umifenovir leads to a higher rate of resolution of disease symptoms on the third day of therapy compared to placebo. In 60 hours after the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza is more than 5 times higher than in the placebo group. A significant effect of umifenovir on the rate of elimination of the influenza virus has been established, which, in particular, is manifested by a decrease in the frequency of detection of RNA virus on the 4th day.
It belongs to low-toxic drugs (LD50>4 g/kg). It does not have any negative effect on the human body when administered orally in recommended doses.
Indications
Prevention and treatment of influenza A and B and other acute respiratory viral infections in adults and children from 6 years old (for dosage form of 100 mg capsules).
Complex therapy of recurrent herpetic infection.
The prevention of postoperative infectious complications.
Contraindications .
Hypersensitivity to umifenovir or to any component of the drug, children under 3 years of age (for dosage form 50 mg), under 6 years of age (for dosage form 100 mg), first trimester of pregnancy, breast-feeding.
With caution:
Second and third trimesters of pregnancy.
Dosage and administration.
- Inside, before a meal.
- Single dose: For children aged 3 to 6 – 50 mg, 6 to 12 years – 100 mg (1 capsule of 100 mg or 2 capsules of 50 mg), over 12 years and adults – 200 mg (2 capsules of 100 mg or 4 capsules of 50 mg).
- For non-specific prophylaxis and treatment of influenza and other acute respiratory infections in children and adults:
- Nonspecific prophylaxis:
- During epidemics of influenza and other acute respiratory infections: to children from 3 to 6 years – 50 mg, from 6 to 12 years – 100 mg, over 12 years and adults – 200 mg twice a week for 3 weeks.
- In direct contact with patients with influenza and other acute respiratory viral infections: In children 3 to 6 years old – 50 mg, 6 to 12 years old – 100 mg, over 12 years old and adults – 200 mg once a day for 10 to 14 days.
- Treatment of influenza and other acute respiratory infections: For children 3 to 6 years old – 50 mg, 6 to 12 years old – 100 mg, over 12 years old and adults – 200 mg 4 times a day (every 6 hours) for 5 days.
- In treatment of recurrent herpes infection: For children 3 to 6 years old – 50 mg, 6 to 12 years old – 100 mg, over 12 years old and adults – 200 mg 4 times daily (every 6 hours) for 5-7 days, then a single dose twice a week for 4 weeks.
- Prevention of postoperative infectious complications: For children 3 to 6 years old – 50 mg, 6 to 12 years old – 100 mg, over 12 years old and adults – 200 mg 2 days before surgery and then on the 2nd and 5th day after surgery.
- Administration of the drug shall be started from the moment of the appearance of the first symptoms of flu and other acute respiratory infections, preferably within 3 days from the beginning of the disease. If after using the drug for three days during the treatment of influenza and other acute respiratory viral infections the severity of symptoms, including high fever (over 38 ° C and more) remains, you should consult a doctor to assess the validity of the drug.
- Use the drug only according to the indications, the method of administration and in the doses specified in the instructions.
